je.st
news
Home
› Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d
Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d
2014-02-05 07:38:22| drugdiscoveryonline Home Page
Furiex Pharmaceuticals, Inc. recently announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain
Tags: with
results
iii
positive
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||